Onconetix, Inc. (ONCO) · Oct 26, 2026 · Other events

Onconetix reverse split uses full 1-for-100 authority

1-for-10 reverse split — Aggregate reverse split reaches the authorized 1-for-100 maximum

Onconetix’s reverse split cuts shares 10-for-1 on November 6, using its full authorized capacity without changing the underlying business.

Onconetix is a cash-hungry commercial-stage biotech trying to move Proclarix toward broader U.S. commercialization through Labcorp, while its latest quarterly filing says it has not established sustained positive cash flow and still needs significant capital.

This is capital-market maintenance, not business progress. The Board approved another 1-for-10 reverse split, effective November 6, 2026, reducing shares from about 5.9 million to roughly 589,000. 〔0〕 〔1〕

The filing uses the company’s full approved reverse-split capacity. Combined with the 1-for-10 split completed in May, this reaches the stockholders’ authorized aggregate maximum of 1-for-100. 〔2〕 The direction was therefore partly known rather than a surprise. Onconetix previously said its May split was primarily intended to address Nasdaq’s minimum-bid requirement, so the new action appears to be another attempt to preserve listing flexibility, although this filing does not state that rationale explicitly.

It does not add funding, revenue, or a Proclarix milestone. Authorized shares remain at 250 million, so the split changes the share count and trading mechanics—not the company’s assets, ownership economics, commercialization progress, or financing position. 〔3〕

Bottom line: The action may help maintain market access, but it does not advance Proclarix or solve Onconetix’s funding challenge. The main message is continued capital-structure pressure, not an operating development.

What to watch next

Reverse split effective November 6, 2026

Original filing on SEC EDGAR

More Onconetix, Inc. news

Onconetix reverse split uses full 1-for-100 authority | ONCO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.